NZ599456A - Assays for the detection of anti-tnf drugs and autoantibodies - Google Patents

Assays for the detection of anti-tnf drugs and autoantibodies

Info

Publication number
NZ599456A
NZ599456A NZ599456A NZ59945610A NZ599456A NZ 599456 A NZ599456 A NZ 599456A NZ 599456 A NZ599456 A NZ 599456A NZ 59945610 A NZ59945610 A NZ 59945610A NZ 599456 A NZ599456 A NZ 599456A
Authority
NZ
New Zealand
Prior art keywords
tnfαlpha
labelled
drug
amount
complex
Prior art date
Application number
NZ599456A
Other languages
English (en)
Inventor
Sharat Singh
Shui Long Wang
Linda Ohrmund
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Priority to NZ621655A priority Critical patent/NZ621655A/en
Publication of NZ599456A publication Critical patent/NZ599456A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
NZ599456A 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies NZ599456A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ621655A NZ621655A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US25504809P 2009-10-26 2009-10-26
US26287709P 2009-11-19 2009-11-19
US32463510P 2010-04-15 2010-04-15
US34556710P 2010-05-17 2010-05-17
US35126910P 2010-06-03 2010-06-03
US38967210P 2010-10-04 2010-10-04
US39358110P 2010-10-15 2010-10-15
PCT/US2010/054125 WO2011056590A1 (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Publications (1)

Publication Number Publication Date
NZ599456A true NZ599456A (en) 2014-06-27

Family

ID=43618083

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ621655A NZ621655A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies
NZ706187A NZ706187A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies
NZ599456A NZ599456A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ621655A NZ621655A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies
NZ706187A NZ706187A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Country Status (15)

Country Link
US (5) US8574855B2 (enExample)
EP (1) EP2494352B1 (enExample)
JP (3) JP5697677B2 (enExample)
KR (2) KR101881714B1 (enExample)
CN (2) CN104634955B (enExample)
AU (4) AU2010315547C1 (enExample)
BR (1) BR112012009855A2 (enExample)
CA (2) CA3108458A1 (enExample)
ES (1) ES2796530T3 (enExample)
IL (2) IL219315B (enExample)
MX (2) MX2012004877A (enExample)
NZ (3) NZ621655A (enExample)
RU (2) RU2015148676A (enExample)
WO (1) WO2011056590A1 (enExample)
ZA (2) ZA201203717B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024752A1 (ja) 2002-09-11 2004-03-25 Chugai Seiyaku Kabushiki Kaisha タンパク質精製方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA3108458A1 (en) 2009-10-26 2011-05-12 Societe Des Produits Nestle S.A. Assays for the detection of anti-tnf drugs and autoantibodies
KR101934247B1 (ko) 2010-10-18 2019-01-02 네스텍 소시에테아노님 항-약물 항체 동종형의 확인 방법
DK2676137T3 (en) * 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
RU2013154566A (ru) 2011-05-10 2015-06-20 Нестек С.А. Способы анализа профиля активности болезни с целью проведения индивидуального лечения
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
HK1202628A1 (en) * 2011-11-30 2015-10-02 Abbvie Deutschland Gmbh & Co Kg Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
EP2823310B1 (en) * 2012-03-08 2018-06-20 F.Hoffmann-La Roche Ag Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes
US20130295685A1 (en) * 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US10132736B2 (en) 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
EP3640645A1 (en) 2012-10-05 2020-04-22 Prometheus Biosciences, Inc. Methods for predicting and monitoring mucosal healing
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
EP2997371B1 (en) * 2013-05-16 2018-11-07 University of Pretoria A method of diagnosing tuberculosis
WO2015083085A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
EP3654037A1 (en) 2013-12-03 2020-05-20 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
CA2965095A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis
CA2969326A1 (en) 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
HK1244880B (en) * 2014-12-05 2020-06-05 Precision Ibd, Inc. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
WO2016110595A1 (en) * 2015-01-09 2016-07-14 Atonomics A/S A UNIVERSAL ASSAY FOR DETERMINING THE QUANTITY OF TNFα INHIBITORY DRUGS AND THEIR CORRESPONDING ANTI-DRUG-ANTIBODIES
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
ES2815224T3 (es) 2015-11-06 2021-03-29 Promise Proteomics Un método para cuantificar anticuerpos terapéuticos
ES2716900T3 (es) * 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
WO2017201142A1 (en) * 2016-05-17 2017-11-23 Memorial Sloan Kettering Cancer Center Treatment of lung adenocarcinoma
CN109791142B (zh) 2016-07-08 2022-11-29 W 健康公司 用于确定样品中治疗性单克隆抗体及其相应抗药物抗体的量的通用测定
EP3695229A1 (en) 2017-10-10 2020-08-19 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
WO2019204747A1 (en) * 2018-04-20 2019-10-24 Janssen Biotech, Inc. Transition analysis method for chromatography column qualification
EP3935396A1 (en) * 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
KR102562006B1 (ko) 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (ja) 1991-09-09 1993-03-19 Tosoh Corp 物質の分析方法
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE69426223T2 (de) 1993-09-07 2001-05-23 Wako Pure Chemical Industries, Ltd. Verfahren und Reagenz zur Messung der Komplementaktivität
JPH07110331A (ja) * 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd ヒト補体価測定方法及びヒト補体価測定用試薬組成物
JPH07140144A (ja) 1993-11-19 1995-06-02 S R L:Kk アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法
DE69530415T2 (de) * 1994-12-28 2004-02-12 University Of Kentucky Rekombinierte sequenzen des monoklonalen anti-idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind
BRPI9707379C8 (pt) * 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
KR20030097576A (ko) 1996-08-12 2003-12-31 세키스이가가쿠 고교가부시키가이샤 세포기능 측정용 용기 및 세포기능 측정방법
JP3718435B2 (ja) * 1996-08-12 2005-11-24 積水化学工業株式会社 細胞機能測定用容器及び細胞機能測定方法
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AU766149B2 (en) * 1998-10-31 2003-10-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variants of humanized anti-carcinoma monoclonal antibody CC49
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
DE19858777B4 (de) * 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen
AU776395B2 (en) * 1999-12-06 2004-09-09 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Aminobenzophenones as inhibitors of IL-1beta and TNF-alpha
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
JP2004500063A (ja) 1999-12-16 2004-01-08 アムジェン　インコーポレイテッド Ｔｎｆｒ／ｏｐｇ様分子およびその使用
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE476654T1 (de) 2001-03-02 2010-08-15 Activx Biosciences Inc Plattform für protein-profiling
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030040027A1 (en) 2001-08-16 2003-02-27 Gerd Ritter Method for determining protein component in a biological sample
ATE469176T1 (de) 2001-11-12 2010-06-15 Merck Patent Gmbh Modifizierter anti-tnf antikörper
IL158297A0 (en) 2001-12-05 2004-05-12 Cangene Corp Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004012673A2 (en) 2002-08-01 2004-02-12 Wyeth, Methods and reagents relating to inflammation and apoptosis
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CA2529759A1 (en) 2003-06-20 2005-10-13 University Of Florida Biomarkers for differentiating between type 2 and type 2 diabetes
KR20070008501A (ko) * 2003-08-01 2007-01-17 암젠 인코퍼레이티드 결정성 종양 괴사 인자 수용체 2 폴리펩티드
CA2535804A1 (en) 2003-08-14 2005-03-03 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
CA2572263A1 (en) 2004-06-30 2006-01-12 Centocor, Inc. Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
CN101223448B (zh) 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
US9580506B2 (en) 2005-07-21 2017-02-28 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
EP1937307A4 (en) 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS
US7542502B2 (en) 2005-09-27 2009-06-02 Cymer, Inc. Thermal-expansion tolerant, preionizer electrode for a gas discharge laser
CA2626859A1 (en) * 2005-11-08 2007-05-18 Medarex, Inc. Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
JP2007147367A (ja) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
DE102005057920A1 (de) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben
WO2008008349A2 (en) 2006-07-11 2008-01-17 Drexel University Methods of quantitatively assessing inflammation with biosensing nanoparticles
US20080286774A1 (en) 2007-05-16 2008-11-20 The Regents Of The University Of California Real-time individualized therapy evaluation
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
WO2009091240A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
US20090234202A1 (en) 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
CA3108458A1 (en) 2009-10-26 2011-05-12 Societe Des Produits Nestle S.A. Assays for the detection of anti-tnf drugs and autoantibodies
KR101934247B1 (ko) 2010-10-18 2019-01-02 네스텍 소시에테아노님 항-약물 항체 동종형의 확인 방법
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
BR112015012482A2 (pt) 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
HK1244880B (en) 2014-12-05 2020-06-05 Precision Ibd, Inc. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

Also Published As

Publication number Publication date
AU2015202899B2 (en) 2017-06-01
NZ706187A (en) 2016-09-30
CN102695955B (zh) 2015-03-18
KR101881714B1 (ko) 2018-07-24
US8574855B2 (en) 2013-11-05
JP2015148616A (ja) 2015-08-20
AU2010315547B2 (en) 2015-03-05
CN102695955A (zh) 2012-09-26
ES2796530T3 (es) 2020-11-27
KR101761541B1 (ko) 2017-07-26
RU2571489C2 (ru) 2015-12-20
ZA201504548B (en) 2019-10-30
AU2010315547C1 (en) 2015-06-04
AU2010315547A1 (en) 2012-05-10
US20140057367A1 (en) 2014-02-27
WO2011056590A1 (en) 2011-05-12
BR112012009855A2 (pt) 2018-06-26
CA2778454C (en) 2021-03-02
US20200018751A1 (en) 2020-01-16
IL219315B (en) 2018-01-31
JP2013508739A (ja) 2013-03-07
AU2017213584A1 (en) 2017-08-31
US8865417B2 (en) 2014-10-21
CN104634955B (zh) 2016-09-14
AU2015202899A1 (en) 2015-06-18
RU2015148676A (ru) 2019-01-15
JP5878253B2 (ja) 2016-03-08
IL256728A (en) 2018-04-09
NZ621655A (en) 2015-08-28
AU2017213584B2 (en) 2019-04-18
US20120329172A1 (en) 2012-12-27
KR20120108978A (ko) 2012-10-05
AU2019205009A1 (en) 2019-08-01
RU2015148676A3 (enExample) 2019-06-18
US9506920B2 (en) 2016-11-29
RU2012121710A (ru) 2013-12-10
US20170184588A1 (en) 2017-06-29
EP2494352B1 (en) 2020-04-08
US20150024404A1 (en) 2015-01-22
CN104634955A (zh) 2015-05-20
JP2016106222A (ja) 2016-06-16
JP5697677B2 (ja) 2015-04-08
MX2012004877A (es) 2012-05-23
KR20170088437A (ko) 2017-08-01
CA2778454A1 (en) 2011-05-12
EP2494352A1 (en) 2012-09-05
ZA201203717B (en) 2018-11-28
US10386366B2 (en) 2019-08-20
CA3108458A1 (en) 2011-05-12
JP6082831B2 (ja) 2017-02-15
IL219315A0 (en) 2012-06-28
MX343328B (es) 2016-11-01

Similar Documents

Publication Publication Date Title
NZ599456A (en) Assays for the detection of anti-tnf drugs and autoantibodies
NZ609363A (en) Methods for determining anti-drug antibody isotypes
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
NZ608384A (en) Biomarkers of renal injury
NZ629703A (en) Methods and compositions for detecting multiple analytes with a single signal
MX357119B (es) Microarn plasmáticos para la detección de cáncer colorrectal temprano.
EP3933406A3 (en) Antibodies to risperidone and use thereof
WO2010096154A3 (en) Compositions and methods for diagnosis and prognosis of colorectal cancer
EP4361608A3 (en) Signal encoding and decoding in multiplexed biochemical assays
WO2012082742A3 (en) Detecting cancer with anti-ccl25 and anti-ccr9 antibodies
WO2011008030A3 (ko) 핵산 검출용 크로마토그래피 시스템
HK1259001A1 (zh) 癌症的预後和诊断方法
EP4570924A3 (en) Chromophore-based characterization and detection methods
WO2011062407A3 (ko) 분석물질의 검출 방법 및 장치
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
WO2012145270A3 (en) Luminescent polymer cyclic amplification
WO2013049704A3 (en) Method and system of particle-phage epitope complex
GB201206977D0 (en) An enzyme detection device
SG10201806729VA (en) Novel assay to detect human periostin
WO2012071344A3 (en) Nucleotide-based probes and methods for the detection and quantification of macromolecules and other analytes
WO2009072441A1 (ja) 検出方法および検出キット
WO2010144808A3 (en) Identification of dsg-3 as a biomarker for the detection of metastasis in lymph nodes
GB201017256D0 (en) Sensor and method
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
IN2014DN10649A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2015 BY SHELSTON IP

Effective date: 20150121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2016 BY CPA GLOBAL

Effective date: 20151002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2017 BY CPA GLOBAL

Effective date: 20160909

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2018 BY CPA GLOBAL

Effective date: 20170914

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2019 BY CPA GLOBAL

Effective date: 20180913

ASS Change of ownership

Owner name: SOCIA TA DES PRODUITS NESTLA S.A., CH

Effective date: 20190627

LAPS Patent lapsed